Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis

Dr. Falk Pharma and Renexxion Advance Naronapride to Late-Stage Development

Dr. Falk Pharma and Renexxion Ireland are advancing naronapride into late-stage development for the treatment of gastroparesis, following positive results from the 328-patient global Phase 2b MOVE-IT study (NCT05621811). This significant milestone moves the partnership closer to regulatory approval in the US and Europe. Renexxion plans to leverage future Phase 3 results to file a New Drug Application with the FDA. Naronapride, an oral, locally acting pan-GI prokinetic, has demonstrated a favorable safety and tolerability profile across multiple prior clinical trials and is designed to address the significant unmet need in gastroparesis by enhancing coordinated motility across the digestive tract.

• Dr. Falk Pharma and Renexxion are progressing naronapride into pivotal studies for gastroparesis, marking a crucial step in their global development program. This decision follows encouraging positive results from the Phase 2b MOVE-IT study. Renexxion intends to utilize the upcoming Phase 3 trial data to submit a New Drug Application (NDA) to the FDA for approval in the US, with a broader goal of securing approval in both the US and Europe, addressing a significant unmet medical need.
• The advancement is underpinned by positive outcomes from the 328-patient global Phase 2b MOVE-IT study (NCT05621811), which evaluated naronapride in gastroparesis. Dr. Kai Pinkernell of Dr. Falk Pharma highlighted that these results reinforce the program's commitment and the drug's potential to significantly impact patients suffering from this debilitating gastrointestinal disorder, characterized by delayed gastric emptying and severe symptoms.
• Naronapride is described as a potential best-in-class oral, locally acting pan-GI prokinetic with a differentiated dual mechanism of action: 5-HT4 receptor agonism and dopamine D2 receptor antagonism. This dual action modulates key targets on the intestinal wall to regulate GI motility and nausea signaling. Its minimal systemic bioavailability and targeted activity within the GI tract are designed to limit systemic exposure, contributing to its favorable safety and tolerability profile observed across previous Phase 1 and Phase 2 trials.

The Persistent Challenges in Gastroparesis Treatment

Current gastroparesis treatment faces multifaceted challenges that significantly impact patient outcomes and therapeutic success. These limitations span across drug efficacy, comorbidity management, and diagnostic complexities that complicate clinical decision-making.

• Treatment failure in comorbid conditions: Gastroparesis significantly increases treatment failure rates in related procedures, with median arcuate ligament release showing a hazard ratio of 1.83 (95% CI, 1.09-3.09; P = .023) for patients with gastroparesis history

• Proton pump inhibitor resistance: Delayed gastric emptying represents one of the most pertinent mechanisms underlying PPI failure in GORD patients, alongside weakly acidic reflux, duodenogastro-oesophageal reflux, and visceral hyperalgesia

• Pharmacokinetic variability in diabetic patients: Delayed gastric emptying in diabetes mellitus leads to altered drug absorption, distribution, metabolism and clearance, resulting in unpredictable pharmacodynamic responses and increased risk of treatment failure or adverse effects

• GLP-1 receptor agonist complications: Medications including semaglutide, liraglutide and tirzepatide may predispose patients to micronutrient deficiencies through appetite suppression, delayed gastric emptying and altered absorption mechanisms

• Diagnostic monitoring limitations: While real-time MRI shows promise as a non-invasive alternative to conventional diagnostic tools for assessing gastric motility and therapeutic monitoring, current diagnostic approaches remain complex and require specialized expertise

• Gastroesophageal barrier dysfunction: In early reflux disease, delayed gastric emptying causes transient loss of the gastroesophageal barrier, contributing to overeating and gastric distention that complicates symptom management

Naronapride's Favorable Safety and Tolerability Profile

Based on the available literature through January 2013, naronapride safety data is primarily derived from a single randomized controlled trial in adults with chronic constipation. This study was part of a broader analysis of highly selective 5-HT4 agonists, which included 13 eligible trials examining this therapeutic class. The limited representation of naronapride-specific data reflects the early stage of its clinical development compared to other agents in this class, such as prucalopride, which comprised the majority of studies reviewed.

The safety profile observed with naronapride and other highly selective 5-HT4 agonists demonstrated that adverse events occurred more frequently compared to control groups, but these events were characterized as generally minor in nature. Headache emerged as the most commonly reported adverse event across the highly selective 5-HT4 agonist class, including naronapride. The trial duration was limited to a maximum of 12 weeks, which constrains the assessment of long-term safety considerations for naronapride specifically.

The overall analysis concluded that highly selective 5-HT4 agonists, including naronapride, exhibited a favorable safety profile in the treatment of chronic constipation. However, the paucity of naronapride-specific adverse event data and safety information across different indications limits the ability to draw definitive conclusions about its comparative tolerability versus standard of care treatments. This favorable safety assessment supports the continued development and use of highly selective 5-HT4 agonists in chronic constipation management, though additional naronapride-specific studies would strengthen the evidence base for this particular agent.

Naronapride's Advance: A New Horizon for Gastroparesis Treatment

The progression of naronapride into late-stage clinical development for gastroparesis marks a pivotal moment for patients grappling with this debilitating condition and for the pharmaceutical landscape. Gastroparesis, characterized by delayed gastric emptying and symptoms ranging from nausea and vomiting to early satiety and abdominal pain, significantly impacts quality of life and can have serious consequences, particularly for diabetic patients where it complicates glycemic control.

For too long, therapeutic options have been limited and fraught with challenges. Current prokinetic agents, while offering some relief, often come with caveats. Metoclopramide, a mainstay, has shown variable efficacy and can be less effective than newer alternatives in certain populations. Older 5-HT4 agonists like cisapride and tegaserod faced significant safety concerns, including cardiovascular adverse events, leading to restricted use or withdrawal. Even erythromycin, a potent prokinetic, carries risks of drug interactions and cardiac complications, and its efficacy has been inconsistent across studies. This historical context underscores a persistent unmet medical need, as evidenced by the stagnant use of prokinetics over the past decade compared to the rise in antiemetics and neuromodulators.

Naronapride, an oral, locally acting pan-GI prokinetic, offers a promising path forward. As a selective 5-HT4 agonist, it aims to enhance coordinated motility across the digestive tract with a favorable safety and tolerability profile observed in earlier trials. This selectivity is crucial, as it may mitigate the cardiovascular risks seen with less selective predecessors. However, the path to market is not without its hurdles. Clinical trials for gastrointestinal disorders often contend with a notable placebo effect, meaning naronapride must demonstrate robust and statistically significant efficacy in its larger Phase 3 studies. Furthermore, while early safety data are encouraging, comprehensive long-term cardiovascular safety monitoring will be paramount, given the class history. The competitive environment is also evolving, with other novel prokinetics and non-pharmacological interventions emerging. Should naronapride successfully navigate these challenges, it could redefine the standard of care for gastroparesis, offering a much-needed, safer, and more effective treatment option for millions of patients.